Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711989 | 0.89 | MAPT (0.63) | MAPTKMT2AMEN1RXFP1CA1 | |
| SCHEMBL9885783 | 0.87 | MAPT (0.62) | MAPTKMT2AMEN1THRBRXFP1 | |
| SCHEMBL14047251 | 0.83 | MAPT (0.58) | MAPTKMT2AMEN1THRBRXFP1 | |
| SCHEMBL9887849 | 0.82 | MAPT (0.62) | MAPTKMT2AMEN1THRBRXFP1 | |
| SCHEMBL11930741 | 0.79 | CA1 (0.76) | MAPTKMT2AMEN1THRBCA1 | |
| SCHEMBL17320001 | 0.72 | CA1 (0.56) | MAPTKMT2AMEN1THRBCA1 | |
| SCHEMBL14316971 | 0.71 | CA1 (0.78) | MAPTKMT2AMEN1THRBRXFP1 | |
| SCHEMBL14315047 | 0.71 | CA1 (0.76) | MAPTKMT2AMEN1THRBCA1 | |
| SCHEMBL2664521 | 0.69 | CA1 (0.76) | MAPTKMT2AMEN1THRBRXFP1 | |
| SCHEMBL3974838 | 0.69 | CA1 (0.78) | KMT2AMEN1THRBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2845849-A1 | Therapeutic cyclopentane derivatives | ALLERGAN, INC. (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2007140197-A1 | THERAPEUTIC PYRROLIDINE COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140136-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC | 2007-11-22 | — | — | US | disclosed |
| WO-2007134085-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007130890-A2 | CYCLOPENTANE-DERIVATIVES AND THEIR USE AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130902-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007131012-A1 | 12-ARYL OR HETEROARYL PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | PTGIR, PTGIS, PTGS1 | MAPT 2775/4885KMT2A 4604/4885MEN1 4618/4885 |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | MAPT 2528/4885KMT2A 4022/4885MEN1 2538/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | MAPT 3495/4885KMT2A 2970/4885MEN1 3829/4885 |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | MAPT 1936/4885KMT2A 4810/4885MEN1 1621/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | MAPT 1422/4885KMT2A 3683/4885MEN1 1873/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | MAPT 3495/4885KMT2A 2970/4885MEN1 3829/4885 |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ABCB1, CYP11B2, SLC10A1 | MAPT 1179/4885KMT2A 4418/4885MEN1 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.